Pfizer won a bidding war for obesity‑drug developer Metsera with an up‑to $10 billion proposal, offering $86.25 per share and edging out Novo Nordisk’s rival offer. The deal resolves an intense auction for Metsera’s next‑generation obesity assets and closes a chapter of litigation between bidders, according to MedCity News coverage. The acquisition underscores Big Pharma’s continued appetite for obesity therapeutics and consolidates competition around oral and injectable next‑generation weight‑loss mechanisms.